Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR...

Area of Science:

• Oncology
• Genetics
• Immunotherapy

Background:

• Epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) represent a rare but distinct molecular subtype of non-small cell lung cancer (NSCLC).
• Targeted therapies for NSCLC with EGFR ex20ins are under active clinical development.
• Understanding the unique characteristics and treatment outcomes of EGFR ex20ins NSCLC is crucial for optimizing patient care.

Purpose of the Study:

• To characterize the clinical outcomes of patients with NSCLC harboring EGFR exon 20 insertions.
• To investigate the genomic and immunophenotypic features of EGFR ex20ins NSCLC.
• To compare treatment responses in EGFR ex20ins NSCLC with other NSCLC subtypes.

Main Methods:

• Retrospective identification and analysis of patients with NSCLC and EGFR ex20ins.
• Comparison of clinical outcomes, including overall survival and time to treatment discontinuation, with NSCLC patients lacking targetable oncogenes.
• Assessment of tumor mutational burden (TMB) and PD-L1 expression in EGFR ex20ins tumors.

Main Results:

• EGFR ex20ins NSCLC occurred in 2% of 6,290 patients and was more prevalent in Black and Asian populations.
• Tumors with EGFR ex20ins exhibited lower TMB and PD-L1 expression compared to other NSCLCs.
• Patients with EGFR ex20ins showed improved overall survival and longer time to treatment discontinuation with platinum chemotherapy, but not with immune checkpoint inhibitors.

Conclusions:

• EGFR ex20ins NSCLC patients demonstrate improved prognosis with platinum chemotherapy, suggesting a distinct response profile.
• Lower TMB and PD-L1 expression in EGFR ex20ins tumors may correlate with reduced benefit from immune checkpoint inhibitors.
• Development of novel molecularly targeted therapies is essential to enhance treatment efficacy for patients with EGFR ex20ins NSCLC.